Showing results (121-130 of 192) with videos related to
Sort By:
Pageof 20
Leukemia Research|December 8, 2005
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Francis J Giles, William T Bellamy, Zeev Estrov, et al.Leukemia|November 26, 2022
Biological drivers of clinical phenotype in myelofibrosisJohn Mascarenhas, Hélène F E Gleitz, Helen T Chifotides, et al.Oncotarget|September 30, 2015
TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromesKathy L McGraw, Thomas Cluzeau, David A Sallman, et al.Cancer Research|May 20, 2016
Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41Ashley A Basiorka, Kathy L McGraw, Leentje De Ceuninck, et al.Leukemia Research|July 30, 2019
Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)Seongseok Yun, Rohit Sharma, Onyee Chan, et al.Acta Haematologica|April 19, 2013
B-lymphoblastic leukemia/lymphoma associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : rare case and review of the literatureJanese Trimaldi, Estrella M Carballido, Jeremy W Bowers, et al.Leukemia & Lymphoma|February 25, 2020
Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1Lynh Nguyen, Xiaohui Zhang, Evans Roberts, et al.American Journal of Hematology|October 24, 2012
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromesRami S Komrokji, Maria Corrales-Yepez, Mohamed A Kharfan-Dabaja, et al.Journal of Hematology & Oncology|March 7, 2012
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomideYuka Sugimoto, Mikkael A Sekeres, Hideki Makishima, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid LeukemiaKendra Sweet, Rami Komrokji, Eric Padron, et al.Pageof 20